SGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance.
Galderisi A, Tamborlane W, Taylor SI, Attia N, Moretti C, Barbetti F. SGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance. Pediatrics 2022, 150 PMID: 35652305, DOI: 10.1542/peds.2021-055671.Peer-Reviewed Original ResearchMeSH KeywordsBenzhydryl CompoundsBlood GlucoseChildDiabetes Mellitus, Type 2FemaleGlycated HemoglobinGlycemic ControlHumansHypoglycemic AgentsInsulinInsulin ResistanceMaleSodium-Glucose Transporter 2 InhibitorsConceptsRabson-Mendenhall syndromeGlycemic controlHemoglobin A1cRenal calcium excretionInsulin-resistant diabetesSevere insulin resistanceCalcium excretionUrinary calciumAntidiabetic treatmentDay doseDose escalationSecond patientFirst patientInsulin levelsInsulin resistanceUrinary excretionSerum glucosePatientsEmpagliflozinMild increaseDapagliflozinΒ-hydroxybutyrateTarget rangeA1CExcretion